In long-term communication with global R&D scientists, inconsistent sensitivity, specificity and repeatability of CAR-T detection have consistently remained core bottlenecks across preclinical and clinical CAR-T projects. CytoArt develops dedicated anti-idiotype antibody products to resolve such detection pain points, adapting to the shifting technical demands as more CAR-T pipelines advance toward clinical trials.
Besides core CAR-T detection reagents, our R&D team has built two complementary technical platforms:
• Customized detection antibodies covering diversified mainstream CAR target sequences
• VHH nanobody development platform supporting CAR construct design and in vivo CAR-T delivery research
• Customized detection antibodies covering diversified mainstream CAR target sequences
• VHH nanobody development platform supporting CAR construct design and in vivo CAR-T delivery research
We sincerely invite all teams developing CAR-T and novel cell therapy pipelines to visit Booth #803 for technical exchange and personalized project consultation.
